Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

This London-based startup uses AI and robotics to discover protein therapeutics; raises €12.8M

Editorial team by Editorial team
October 30, 2020
in (Crowd)funding, AI and chatbots, Health & Medtech, News
0
ai
24
SHARES
LinkedInTwitterWhatsAppFacebook

The growth in Artificial Intelligence (AI) technology integration is increasing rapidly in various sectors. A lot of startups across the world are creating new approaches and seeking innovative business models in a bid to disrupt the pharmaceutical industry. 

As per a report, the global artificial intelligence (AI) in the drug discovery market is expected to grow from $1.60B (approx €1.3B) in 2019 to $40.36B (approx €34.55B) by 2027, at a CAGR of 49.6% during the forecast period 2020-2027.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Many pharmaceutical and biotech companies are using AI technology integration to focus on drug development in order to discover the drugs for the most complex diseases such as Alzheimer’s and pancreatic cancer. AI helps these companies to streamline their R&D activities for personalised medicines and complex drug discovery.

Raises $15M

In a recent development, a London-based biotech company that uses machine learning to develop new therapeutics, LabGenius, has raised an additional $15M (approx €12.8M) in its Series A round of funding. The round was led by Atomico, and partner Irina Haivas will join the startup’s board. 

Other investors include those that participated in the first close of the round last year, Lux Capital, Obvious Ventures, Kindred Capital, and Inovia Capital.

The additional capital brings the company’s total Series A funding to $25M (approx €21.4M). The funds raised will be used to accelerate the growth of LabGenius’s underlying technology platform and its product.

About LabGenius

Founded in 2012 by Dr. James Field, LabGenius is a drug discovery company that uses artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.

The company has developed EVA – a robot scientist capable of designing, conducting, and learning from its own experiments. Importantly, the learning aspect means that EVA gets continuously smarter as it unpicks the genetic design rules that underpin life.

The LabGenius team includes experts in protein engineering, synthetic biology, software engineering, data science, and robotic automation.

Protein therapeutic through technology

According to LabGenius, protein therapeutics represent 30% of total pharmaceutical sales. Since the first protein therapeutic was approved almost 40 years ago, this class of molecules has been used to treat both cancer and chronic diseases like diabetes. However, high costs, risks, and long timeframes associated with their development have limited the ability to bring new treatments to the market.

Currently, the company claims that getting just one new protein therapeutics to the market costs the industry over a billion pounds and can take more than a decade.

Therefore, LabGenius is building a systematic, machine learning-driven platform that,  it claims, will make the discovery of protein therapeutics faster and yield novel drugs that would not have been found using traditional methods. The company claims its technology will help slash the time, cost, and risk associated with developing new drugs.

Irina Haivas, Partner at Atomico says, “The human and economic toll of COVID-19 makes it painfully obvious that we need a faster and better way to develop drugs. R&D in the industry reached a productivity bottleneck many years ago; the only way forward is through technology. LabGenius is taking on the task of applying software and engineering to biology, and doing this in an area of high complexity: proteins.”

Image credit: LabGenius

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: fundingnews
Share2Tweet6SendShare10

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

The Humblebrag launches online course to help emerging leaders amplify their visibility and voice

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Here’s how cryptocurrency will take over the world

Blue Tulip Awards is driven by purpose: why innovation and equality go hand in hand

Breaking news from Amsterdam | Partner

Amsterdam-based Founda Health raises €12.3M to build infrastructure for global healthcare sector; here’s how

Combining financial with human capital in Amsterdam: Volta, LevelUp and Tech Rise on their approach

Here’s why Just Eat Takeaway is expanding its offices in Amsterdam

Amsterdam-based Veylinx uses Nobel Prize-winning approach to solve the problem of unreliable survey data; raises €1.6M

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info